Results 61 to 70 of about 22,527 (249)

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1346-1357, April 2025.
Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and the prognostic impact of ID using different criteria on all‐cause and cardiovascular mortality, as well as first hospitalization for HF in patients with new‐onset chronic HF.
Abdullahi Ahmed Mohamed   +12 more
wiley   +1 more source

Association between diuretic use and the risk of vertebral fracture after stroke: a population-based retrospective cohort study

open access: yesBMC Musculoskeletal Disorders, 2019
Background Stroke is a major risk factor for osteoporosis and fractures. No study has evaluated the association between diuretic use and risk of vertebral fracture in stroke patients, although a considerable proportion of stroke patients are prescribed ...
Shu-Man Lin   +3 more
doaj   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran   +10 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension

open access: yesESC Heart Failure
Aims The use of loop diuretics in pulmonary arterial hypertension (PAH) is less frequent compared with heart failure. The clinical and prognostic characteristics of PAH patients according to loop diuretic use remain unexplored.
Giulio Savonitto   +23 more
doaj   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

open access: yesESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim   +12 more
wiley   +1 more source

Early in‐hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

open access: yesESC Heart Failure, EarlyView.
This state‐of‐the‐art review outlines a practical, evidence‐based framework for early acute heart failure management to address critical gaps in current guidance and improve early treatment outcomes. Key components include early identification of co‐existing conditions, bedside haemodynamic profiling, a structured diagnostic approach incorporating both
Anika S. Naidu   +22 more
wiley   +1 more source

Sushchestvuyut li perspektivy primeneniyapetlevykh diuretikov dlya lecheniyaarterial'noy gipertenzii?

open access: yesКардиоСоматика, 2011
Summary. The paper discusses the indications for use of loop diuretics to treat essential hypertension and the current limits in terms of their introduction into the practice of routine antihypertensive therapy.
Viktor Viktorovich Fomin
doaj  

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

open access: yesESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti   +23 more
wiley   +1 more source

Predicting acute decompensated heart failure using circadian markers from heart rate time series

open access: yesESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy